Moonlake Immunotherapeutics · NASDAQ:MLTX

Bodenstedt Matthias sold 2,426 Moonlake Immunotherapeutics shares (Form 4)

Traded Apr 14, 2026 · Filed Apr 16, 2026

On Apr 14, 2026, Bodenstedt Matthias (Chief Financial Officer) sold 2,426 Moonlake Immunotherapeutics shares at US$19.56 for US$47,453 under a trading plan, leaving 1,186,084 shares. Filed Apr 16, 2026 (Form 4).

Sold
2,426 shares
Price
US$19.56
Value
US$47,453
Holding after
1,186,084 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 14, 2026Class A ordinary shares, par value $0.0001 per shareSale2,426US$19.561,186,084Direct

Source

View original at SEC

Related